Seelos Therapeutics Inc. [NASDAQ: SEEL] plunged by -$0.05 during the normal trading session on Tuesday and reaching a high of $1.15 during the day while it closed the day at $1.08. The company report on August 10, 2020 that Seelos Therapeutics Receives FDA May Proceed Notice to Initiate a Phase IIb/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis.
Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that, on August 7, 2020, it was notified by the Food and Drug Administration (FDA) that Seelos may proceed with initiating a Phase IIb/III trial studying SLS-005 (trehalose) for the treatment of Amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease).
Mutations in the C9orf72, SOD1, FUS, and TARDBP genes can cause familial ALS and contribute to the development of sporadic ALS. These mutations contribute to the death of motor neurons and ALS affected motor neurons develop a buildup of protein aggregates such as TDP-43 and SOD1. In in-vivo studies of ALS, trehalose has been shown to increase clearance of TDP-43, decrease SOD1 and SQSM1/p62 aggregates and monomers, delay the progression of the disease, preserve ventral horn motor neurons and increase muscle fiber size.
Seelos Therapeutics Inc. stock has also loss -1.82% of its value over the past 7 days. However, SEEL stock has inclined by 44.00% in the 3 months of the year. Over the past six months meanwhile, it has gained 40.26% and lost -19.40% year-on date.
The market cap for SEEL stock reached $48.99 million, with 44.95 million shares outstanding and 37.93 million shares in the current float. Compared to the average trading volume of 1.51M shares, SEEL reached a trading volume of 1179874 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Seelos Therapeutics Inc. [SEEL]:
The Benchmark Company have made an estimate for Seelos Therapeutics Inc. shares, keeping their opinion on the stock as Speculative Buy, with their previous recommendation back on November 14, 2019. The new note on the price target was released on May 14, 2019, representing the official price target for Seelos Therapeutics Inc. stock.
The Average True Range (ATR) for Seelos Therapeutics Inc. is set at 0.09, with the Price to Sales ratio for SEEL stock in the period of the last 12 months amounting to 122.47. The Price to Book ratio for the last quarter was 5.40, with the Price to Cash per share for the same quarter was set at 0.28.
SEEL stock trade performance evaluation
Seelos Therapeutics Inc. [SEEL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.82. With this latest performance, SEEL shares gained by 8.00% in over the last four-week period, additionally plugging by 40.26% over the last 6 months – not to mention a drop of -32.50% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SEEL stock in for the last two-week period is set at 48.14, with the RSI for the last a single of trading hit 47.27, and the three-weeks RSI is set at 49.66 for Seelos Therapeutics Inc. [SEEL]. The present Moving Average for the last 50 days of trading for this stock 1.1323, while it was recorded at 1.1100 for the last single week of trading, and 0.9661 for the last 200 days.
Seelos Therapeutics Inc. [SEEL]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Seelos Therapeutics Inc. [SEEL] shares currently have an operating margin of -7399.20. Seelos Therapeutics Inc.’s Net Margin is presently recorded at -13668.00.
Return on Total Capital for SEEL is now -2,163.51, given the latest momentum, and Return on Invested Capital for the company is -3,996.49. Return on Equity for this stock declined to -3,996.49, with Return on Assets sitting at -690.02.
Reflecting on the efficiency of the workforce at the company, Seelos Therapeutics Inc. [SEEL] managed to generate an average of -$8,542,500 per employee.Seelos Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.00 and a Current Ratio set at 2.00.
Earnings per share (EPS) analysis for Seelos Therapeutics Inc. [SEEL] stock
With the latest financial reports released by the company, Seelos Therapeutics Inc. posted -0.09/share EPS, while the average EPS was predicted by analysts to be reported at -0.13/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 30.80%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SEEL.
Seelos Therapeutics Inc. [SEEL]: Insider Ownership positions
There are presently around $6 million, or 12.40% of SEEL stock, in the hands of institutional investors. The top three institutional holders of SEEL stocks are: UNIPLAN INVESTMENT COUNSEL, INC. with ownership of 2,069,121, which is approximately 211.391% of the company’s market cap and around 7.20% of the total institutional ownership; RENAISSANCE TECHNOLOGIES LLC, holding 1,078,379 shares of the stock with an approximate value of $1.17 million in SEEL stocks shares; and SABBY MANAGEMENT, LLC, currently with $0.55 million in SEEL stock with ownership of nearly New of the company’s market capitalization.
Positions in Seelos Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 18 institutional holders increased their position in Seelos Therapeutics Inc. [NASDAQ:SEEL] by around 2,613,013 shares. Additionally, 8 investors decreased positions by around 90,382 shares, while 9 investors held positions by with 2,599,937 shares. The mentioned changes placed institutional holdings at 5,303,332 shares, according to the latest SEC report filing. SEEL stock had 10 new institutional investments in for a total of 1,056,201 shares, while 4 institutional investors sold positions of 37,242 shares during the same period.